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Abstract
Background: Previously, we have demonstrated that human ABCB5 is a full-sized ATP-binding cassette transporter
that shares strong homology with ABCB1/P-glycoprotein. ABCB5-transfected cells showed resistance to taxanes and
anthracyclines. Herein, we further screened ABCB5 substrates, and explored the mechanism of resistance.
Methods: Sensitivity of the cells to test compounds was evaluated using cell growth inhibition assay. Cellular levels
of buthionine sulfoximine (BSO), glutathione and amino acids were measured using HPLC and an enzyme-based
assay. Cellular and vesicular transport of glutathione was evaluated by a radiolabeled substrate. Expression levels
of glutathione-metabolizing enzymes were assessed by RT-PCR.
Results: Human ABCB5-transfected 293/B5-11 cells and murine Abcb5-transfected 293/mb5-8 cells showed 6.5-
and 14-fold higher resistance to BSO than the mock-transfected 293/mock cells, respectively. BSO is an inhibitor
of gamma-glutamylcysteine ligase (GCL), which is a key enzyme of glutathione synthesis. 293/B5-11 and 293/mb5-8
cells also showed resistance to methionine sulfoximine, another GCL inhibitor. A cellular uptake experiment revealed
that BSO accumulation in 293/B5-11 and 293/mb5-8 cells was similar to that in 293/mock cells, suggesting that BSO is
not an ABCB5 substrate. The cellular glutathione content in 293/B5-11 and 293/mb5-8 cells was significantly higher than
that in 293/mock cells. Evaluation of the BSO effect on the cellular glutathione content showed that compared with 293/
mock cells the BSO concentration required for a 50 % reduction in glutathione content in 293/B5-11 and 293/mb5-8 cells
was approximately 2- to 3-fold higher. This result suggests that the BSO resistance of the ABCB5- and Abcb5-transfected
cells can be attributed to the reduced effect of BSO on the transfectants. Cellular and vesicular transport assays showed
that the transport of radiolabeled glutathione in 293/B5-11 cells was similar to that in 293/mock cells. The mRNA
expression of genes encoding glutathione-metabolizing enzymes in 293/B5-11 cells was similar to that in 293/
mock cells. The cellular content of Glu, a precursor of glutathione, in 293/B5-11 and 293/mb5-8 cells was
higher than that in 293/mock cells.
Conclusions: ABCB5/Abcb5-transfected cells showed resistance to BSO, which is not a substrate of ABCB5. Our
results suggest that ABCB5/Abcb5 upregulates cellular glutathione levels to protect cells from various poisons.
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Background
Human ATP-binding cassette (ABC) transporters com-
prise a superfamily of 48 members, which are classified
into seven subfamilies (ABCA–ABCG) according to se-
quence homology. ABCB1/P-glycoprotein is expressed
as a 170–180 kDa transmembrane glycoprotein that
consists of two homologous halves, each containing a
hydrophobic region with six transmembrane segments
and a nucleotide-binding region [1–3]. ABCB1 functions
as an efflux pump for various structurally unrelated anti-
cancer drugs such as vinca alkaloids, anthracyclines and
taxanes [1, 2, 4]. ABCB1 is expressed in a variety of
normal tissues and cells, and plays a key role in the
excretion of various natural compounds and xenobiotics
[2]. Expression of ABCB1 in the apical surface of capillary
endothelial cells in the brain and testis suggests a protect-
ive role of this transporter against toxic substances [2].
ABCG2/BCRP forms a homodimer bridged by a disulfide
bond and mediates resistance to 7-ethyl-10-hydroxycamp-
tothecin, topotecan and mitoxantrone [5, 6]. ABCG2 is
expressed in hematopoietic stem cells and is a determin-
ant of the side-population phenotype [7]. ABCC1/MRP1
mediates resistance to anthracyclines, vinca alkaloids,
folate-based antimetabolites and etoposide [8]. ABCC1 is
expressed in the gastrointestinal tract, liver, kidney and
capillary endothelial cells, and mediates the efflux of a
variety of organic anions, including glutathione and glucu-
ronide conjugates, as well as unconjugated organic anions
such as reduced glutathione (GSH) and folate derivatives.
These findings suggest that ABC transporters have two
major roles: (1) transporting natural substances and
xenobiotics across the lipid bilayer membrane, and (2)
protecting important organs and cells such as the brain,
testis, and hematopoietic and tissue stem cells from
toxic substances.
Previously, we have reported that human ABCB5 is a
full-sized ABC transporter that consists of two homolo-
gous halves, each including a hydrophobic region with six
predicted transmembrane segments and a nucleotide-
binding region, and that it shares strong homology with
ABCB1. ABCB5 confers resistance to taxanes and anthra-
cyclines [9]. The cellular uptake of radiolabeled paclitaxel
and docetaxel by the transfectants was lower than that by
the parental cells. Membrane vesicles prepared from
ABCB5 baculovirus-infected Sf21 cells showed high
vanadate-sensitive ATPase activity that was sensitive to
docetaxel [9]. Expression of full-length ABCB5 has been
observed in the prostate and testis. In addition, it has been
reported that ABCB5 is expressed in human melanoma
tumor-initiating cells [10]. ABCB5-positive melanoma cells
inoculated into immunodeficient mice showed greater
tumorigenic capacity than ABCB5-negative cells [10]. Re-
cently, murine Abcb5 expression has been reported in lim-
bal stem cells, and was required for corneal development
and repair [11]. These results suggest that ABCB5 may also
have a protective function in stem cells.
In this study, human ABCB5- and murine Abcb5-
transfected cells showed resistance to buthionine sulfoxi-
mine (BSO), an inhibitor of gamma-glutamylcysteine
ligase (GCL), which is required for the first step of gluta-
thione synthesis. A transport study showed that BSO is
not a substrate of ABCB5. Our results showed that
ABCB5/Abcb5 upregulates cellular glutathione levels.
The BSO resistance of 293/B5-11 and 293/mb5-8 cells
can be attributed to the lower effect of BSO on the de-
pletion of cellular glutathione content.
Methods
Plasmids
Murine Abcb5 cDNA (GenBank ID: NM_029961) was iso-
lated by PCR using mouse testis cDNA (Takara, Ohtsu,
Japan) as a template. The 5'-fragment of Abcb5 cDNA was
amplified using the primers, -79F (5'-GGAGAAAAGCCA-
CACACGAA-3') and 1853R (5'-TAGTACAGCCCCTGCT
TTGC-3'). The 3'-fragment of Abcb5 cDNA was amplified
using the primers, 1570F (5'-GCTCAAATGAGTGGA
GGCCA-3') and 3791R (5'-CAGTGCACCCAATGAAG-
CAAT-3'). A c-Myc epitope tag was added to the N-
terminus of the coding region by PCR. The two Abcb5
cDNA fragments were sequenced, digested with XhoI,
ligated and cloned into the bicistronic expression plas-
mid, pCAL-IRES-ZEO [12]. The resulting plasmid was
termed pCAL-MycAbcb5-IRES-ZEO.
Cells, transfectants and cell growth inhibition assay
Cells were cultured in Dulbecco’s modified Eagle’s medium
supplemented with 7 % fetal bovine serum at 37 °C in 5 %
CO2. Establishment of human ABCB5-transfected cells has
been described previously [9]. To generate murine Abcb5-
transfected cells, HEK293 cells were transfected with
pCAL-MycAbcb5-IRES-ZEO using the FuGENE HD trans-
fection reagent (Promega, Madison, WI, USA), and then
selected with 50 μg/mL of zeocin for 8 days. Clonal cells
were obtained from the mixed population by a standard
limiting dilution technique. The sensitivity of the transfec-
tants to anticancer agents was evaluated using a cell growth
inhibition assay. Cell numbers were determined using a
Coulter counter (Beckman Coulter, Brea, CA, USA).
Western blot analysis
Protein expression was evaluated by western blotting as
previously described [13]. Expression of Myc-tagged
human ABCB5 and murine Abcb5 was evaluated using
mouse anti-c-Myc monoclonal antibody 9E10 (Roche Diag-
nostics, Indianapolis, IN, USA). Mouse anti-glyceraldehyde
3-phosphate dehydrogenase (GAPDH) monoclonal anti-
body (Chemicon, Temecula, CA, USA) was used as a
protein loading control. The blots were incubated with
Kondo et al. BMC Pharmacology and Toxicology  (2015) 16:37 Page 2 of 10
peroxidase-conjugated secondary antibodies (GE Health-
care, Little Chalfont, UK). The membrane-bound anti-
bodies were visualized using the SuperSignal West Dura
Extended Duration Substrate (Thermo Fisher Scientific,
Waltham, MA, USA).
Transport assay
Intracellular accumulation of BSO was quantified
using an HPLC. Cells were plated at 5 × 106 cells in a
100-mm dish and incubated at 37 °C for 18 h. After
attachment to the plates, cells were incubated with
500 μM BSO for 0, 1 and 3 h. The untreated and
BSO-treated cells were harvested, washed and lysed
by addition of 1 mL of ethanol. The cell debris was
removed by centrifugation at 18,000 × g for 20 min.
The amine-containing compounds including BSO in
the cell extracts were reacted with the fluorescent
derivatizing reagent, 6-aminoquinolyl-N-hydroxysucci-
nimidyl carbamate (AQC; Waters, Milford, MA, USA)
[14]. The resulting fluorescent derivatives were sepa-
rated by HPLC on a 4.6 × 250 mm ID Inertsil ODS3
column (GL Sciences, Tokyo, Japan). Mobile phase A
consisted of 50 mM sodium acetate and 1 % tetra-
hydrofuran, pH 6.6. Mobile phase B was methanol.
The samples were applied onto the column and
eluted at 65 °C at a flow rate of 1 mL/min by the fol-
lowing gradient: 0–25 min, 15–80 % B; 25–26 min,
80–100 % B; 26–46 min, 100 % B. The fluorescent
compounds were detected using a Shimadzu RF-10A
fluorescence detector (Shimadzu, Kyoto, Japan) with
250 nm excitation and 395 nm emission.
Transport of GSH was evaluated by cellular and
vesicular transport assays using [2-glycine-3H]GSH
(49.5 Ci/mmol; American Radiolabeled Chemicals, St.
Louis, MO, USA). For the cellular uptake experiment,
the cells (106/tube) were incubated with 1 nM
[3H]GSH at 37 °C for 0, 2, 5 and 10 min in Hanks’
balanced salt solution. The reaction was terminated
by addition of ice-cold phosphate-buffered saline.
After washing, the radioactivity in the cells was deter-
mined by a liquid scintillation counter. For the ves-
icular transport experiment, membrane vesicles were
prepared according to a method described previously
[13]. The vesicles (25 μg/tube) were incubated with
66 nM [3H]GSH in the absence or presence of 3 mM
ATP at 25 °C for 0, 2 and 10 min in a reaction mix-
ture containing 250 mM sucrose, 10 mM HEPES,
10 mM MgCl2, 10 mM phosphocreatine and 100 μg/mL
creatine kinase. The reaction was terminated by addition
of ice-cold stop solution (250 mM sucrose, 10 mM HEPES
and 100 mM NaCl) and centrifuged at 18,000 × g for
10 min. After washing, the radioactivity in the membrane
vesicles was determined by a liquid scintillation counter.
Determination of cellular glutathione content
Cellular GSH content was measured using an HPLC.
Cells were harvested and lysed by addition of methanol.
The cell debris was removed by centrifugation at
18,000 × g for 20 min. The supernatant was derivatized
using AQC and quantified by an HPLC. The HPLC col-
umn, flow rate, temperature, mobile phase A and B were
the same as in the BSO uptake experiment. The gradient
system was as follows: 0–75 min, 5–35 % B; 75–76 min,
35–100 % B; 76–101 min, 100 % B. The fluorescent
compounds were detected using a Shimadzu RF-10A
fluorescence detector with 250 nm excitation and
395 nm emission.
The effect of BSO on the cellular glutathione content
was measured using a glutathione assay kit (Cayman
Chemical, Ann Arbor, MI, USA) according to the manu-
facturer’s protocol [15]. Briefly, cells were incubated with
various concentrations of BSO for 2 days. The cell
extract was prepared, deproteinized and reacted with
5,5'-dithiobis(2-nitrobenzoic acid). In this reaction,
glutathione reductase was added to convert glutathione
disulfide to GSH. The resulting 5-mercapto-2-nitroben-
zoic acid was quantified colorimetrically.
mRNA expression analysis
Total RNA was extracted from cells using an RNeasy kit
(Qiagen, Valencia, CA, USA) and subjected to a cDNA
microarray analysis using SurePrint G3 Human GE 8 ×
60 K Microarray (Agilent Technologies, Santa Clara,
CA, USA). The mRNA expression of genes encoding en-
zymes involved in glutathione metabolism was also eval-
uated by RT-PCR. The genes analyzed in this study were
glutamate-cysteine ligase catalytic subunit (GCLC), glu-
tamate-cysteine ligase modifier subunit (GCLM), gluta-
thione synthase (GSS), glutathione reductase (GSR) and
glutathione S-transferase pi 1 (GSTP1). Primer sequences
are listed in Table 1. RT-PCR reactions were performed
using an RNA LA PCR kit (Takara). The PCR conditions
were as follows: 94 °C for 5 min, then increasing cycle
numbers of 94 °C for 30 s, 51 °C for 30 s and 72 °C for
1 min, and a final extension step at 72 °C for 7 min.
Determination of cellular amino acids’ content
Cells were incubated at 37 °C for 4 h in fresh medium,
harvested and lysed by addition of methanol. The cell
debris was removed by centrifugation at 18,000 × g for
20 min. The supernatant was derivatized using 4-fluoro-
7-nitro-2,1,3-benzoxadiazole (Dojindo, Kumamoto,
Japan) [16]. The resulting fluorescent derivatives were
separated by an HPLC on a 1.5 × 150 mm CAPCELL
PAK C18 MGII S5 column (Shiseido, Tokyo, Japan).
Mobile phase A consisted of 10 mM citric acid and
75 mM sodium perchlorate, pH 6.2. Mobile phase B was
50 % acetonitrile. The samples were applied onto the
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column and eluted at 50 °C at a flow rate of 0.5 mL/min
with the following gradient: 0–20 min, 3–10 % B;
20–45 min, 10–37 % B; 45–50 min, 37–38 % B; 50–60 min,
38–79 % B; 60–65 min, 79–90 % B; 65–66 min, 90–100 %
B; 66–70 min, 100 % B. The fluorescent compounds were
detected using a Shimadzu RF-10A fluorescence detector
with 480 nm excitation and 530 nm emission.
Results
Resistance of ABCB5- and Abcb5-transfected cells to GCL
inhibitors
We have previously reported that human ABCB5-trans-
fected cells showed resistance to anthracyclines and tax-
anes [9]. In the present study, we tested the sensitivity of
the parental and human ABCB5-transfected cells to vari-
ous anticancer agents and cytotoxic compounds, and
found that the ABCB5-transfected cells showed more re-
sistance to BSO than the control cells. BSO is an inhibi-
tor of GCL, a rate-limiting enzyme of glutathione
synthesis. 293/B5-11 and 293/B5-126 cells, which
expressed high amounts of ABCB5, showed 6.5- and
4.6-fold higher resistance to BSO than 293/mock cells,
respectively, whereas 293/B5-104 and 293/B5-118 cells,
which expressed low amounts of ABCB5, showed only
1.4- and 1.7-fold higher resistance to BSO than 293/
mock cells, respectively (Fig. 1a and b). To confirm that
the BSO resistance of ABCB5 transfectants was due to
the transporter function, we generated murine Abcb5-
transfected HEK293 cells. The expression of Abcb5 in
the zeocin-resistant clones was examined by western
blotting using an anti-c-Myc antibody, and clone 293/
mb5-8, which showed the highest Abcb5 expression was
selected for further experiments (Fig. 1a). The molecular
Table 1 Sequences of primers used in RT-PCR analysis













Fig. 1 Resistance of ABCB5- and Abcb5-transfected cells to BSO and MSO. a Immunoblot analysis of the expression of Myc-tagged human ABCB5
and murine Abcb5 in the transfectants using anti-c-Myc monoclonal antibody 9E10. b Sensitivity of human ABCB5-transfected cells to BSO. Cells
were cultured for 5 days in the absence or presence of various concentrations of BSO. Cell numbers were determined using a Coulter counter.
The data are presented as mean ± SD of triplicate determinations. c Sensitivity of murine Abcb5-transfected cells to BSO. d Sensitivity of ABCB5- and
Abcb5-transfected cells to MSO
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weight of human ABCB5 and murine Abcb5 is approxi-
mately 140 kDa, though the molecular weight of murine
Abcb5 is slightly higher than that of human ABCB5.
Compared with the control, 293/mb5-8 cells showed 14-
fold higher resistance to BSO (Fig. 1c). We next exam-
ined the sensitivity of the ABCB5- and Abcb5-transfected
cells to methionine sulfoximine (MSO), another GCL in-
hibitor with a similar structure to BSO. As shown in
Fig. 1d, 293/B5-11 and 293/mb5-8 cells showed 3.0- and
4.5-fold higher resistance to MSO than 293/mock cells,
respectively. These results indicate that the expression of
ABCB5/Abcb5 confers resistance to GCL inhibitors.
Intracellular accumulation of BSO in ABCB5- and Abcb5-
transfected cells
To explore the mechanism of BSO resistance, we measured
BSO accumulation in the ABCB5- and Abcb5-transfected
cells. 293/mock, 293/B5-11 and 293/mb5-8 cells were incu-
bated with 500 μM BSO for 1 and 3 h, and cell extracts
were derivatized using AQC and subjected to HPLC ana-
lysis. The HPLC chromatograms of the 293/mock cells be-
fore the addition of BSO and 3 h after the addition of BSO
are shown in Fig. 2a and b, respectively. A BSO peak indi-
cated by an arrow was detected at 14.3 min (Fig. 2b),
whereas no peak was detected around 14–15 min in the
chromatogram without BSO treatment (Fig. 2a). As shown
in Fig. 2c, BSO accumulation in 293/B5-11 and 293/mb5-8
cells was similar to that in 293/mock cells. This demon-
strated that the BSO resistance of 293/B5-11 and 293/mb5-
8 cells was not caused by reduced accumulation of BSO.
Cellular glutathione in ABCB5- and Abcb5-transfected cells
We next measured the cellular GSH content in ABCB5-
and Abcb5-transfected cells using HPLC after derivatization
with AQC. A GSH peak was detected at 20 min in the
chromatogram of 293/mock cells (Fig. 3a, peak under
arrow). The GSH peaks in the chromatograms of 293/B5-
11 (Fig. 3b) and 293/mb5-8 (Fig. 3c) cells were higher than
those of 293/mock cells. The cellular GSH content in 293/
mock, 293/B5-11 and 293/mb5-8 cells was 12.8 ± 0.6, 18.4
± 1.3 and 18.0 ± 2.7 nmol/106 cells, respectively (Fig. 3d).
When 293/mock and 293/B5-11 cells were treated with
100 μM BSO for 2 days, the peaks at 20 min disappeared
(Fig. 3e and f, respectively). This excludes the possibility of
contamination of compounds other than BSO in the
20 min peak of 293/B5-11 and 293/mb5-8 cells. Therefore,
these results clearly showed the upregulation of cellular
GSH in ABCB5- and Abcb5-transfected cells.
The GSH transport by ABCB5 was evaluated using
cellular and vesicular transport assays. We first exam-
ined the cellular uptake of [3H]GSH by 293/mock and
293/B5-11 cells; however, no significant uptake was ob-
served (Fig. 3g). In the vesicle transport assay shown in
Fig. 3h, an ATP-dependent uptake of GSH was observed;
however, no significant difference was detected between
293/mock and 293/B5-11 vesicles. This suggests that
GSH is not a substrate of ABCB5.
We then examined whether the BSO resistance of
293/B5-11 and 293/mb5-8 cells is attributed to the effect
of BSO on the depletion of cellular glutathione. 293/
mock and 293/B5-11 cells were cultured for 2 days in
the absence or presence of various concentrations of
BSO, and the cellular glutathione content was measured
using an enzyme-based assay kit. In this experiment, the
cellular glutathione content in the absence of BSO in
293/mock, 293/B5-11 and 293/mb5-8 cells was 3.7 ± 0.4,
7.4 ± 0.5 and 6.6 ± 0.1 nmol/106 cells, respectively
(Fig. 4a). This result confirmed the upregulation of
Fig. 2 Intracellular accumulation of BSO in ABCB5- and Abcb5-transfected cells. a HPLC chromatogram of AQC-derivatized ethanol extract of 293/
mock cells without incubation with BSO. b HPLC chromatogram of AQC-derivatized ethanol extract of 293/mock cells after a 3-h incubation with
500 μM BSO. A BSO peak indicated by an arrow was detected at 14.3 min. c Intracellular accumulation of BSO. 293/mock, 293/B5-11 and 293/mb5-8 cells
were incubated with 500 μM BSO for 1 and 3 h. The intracellular BSO content was determined by HPLC. The data are presented as
mean ± SD of triplicate determinations
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cellular glutathione content in ABCB5- and Abcb5-trans-
fected cells. As shown in Fig. 4b, the cellular glutathione
content was lower in 293/mock cells than in 293/B5-11
cells in each BSO concentration. The BSO concentration
required for reducing the glutathione content by 50 % in
293/mock, 293/B5-11 and 293/mb5-8 cells was 3.0 ±
Fig. 3 Cellular GSH content of ABCB5- and Abcb5-transfected cells. a–c HPLC chromatograms of AQC-derivatized methanol extracts of 293/mock
(a), 293/B5-11 (b) and 293/mb5-8 (c) cells. GSH peaks indicated by arrows were detected at 20 min. d Cellular GSH content in 293/mock,
293/B5-11 and 293/mb5-8 cells determined by HPLC. The data are presented as mean ± SD of triplicate determinations. Asterisks show p < 0.05 by two-
sided t-test. e, f HPLC chromatograms of AQC-derivatized methanol extracts of 293/mock (e) and 293/B5-11 (f) cells after incubation for 2 days in the
presence of 100 μM BSO. g Intracellular accumulation of GSH in 293/mock and 293/B5-11 cells. Cells were incubated with 1 nM [3H]GSH at 37 °C for 0, 2, 5
and 10 min. h ATP-dependent uptake of GSH in 293/mock and 293/B5-11 vesicles. The membrane vesicles were incubated at 25 °C with 66 nM [3H]GSH in
the absence or presence of 3 mM ATP for 0, 2 and 10 min
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0.2 μM, 8.7 ± 0.2 μM and 5.8 ± 0.3 μM, respectively, indi-
cating that 293/B5-11 and 293/mb5-8 cells were 2.9-
and 2.0-fold more resistant to the glutathione-depleting
effect of BSO than 293/mock cells, respectively. These
results suggest that the BSO resistance of 293/B5-11 and
293/mb5-8 cells can be attributed to the lower effect of
BSO on the depletion of cellular glutathione content.
Glutathione metabolism and glutathione precursor amino
acids
A possible reason for the high GSH content in the
ABCB5- and Abcb5-transfected cells is alteration in the
expression of genes encoding glutathione-metabolizing
enzymes. To examine this, mRNA expression was evalu-
ated using SurePrint G3 Human GE 8 × 60K Microarray;
however, we could not find any genes involved in gluta-
thione synthesis and metabolism whose mRNA expres-
sion was significantly altered in 293/B5-11 cells (data
not shown). RT-PCR experiments confirmed that there
was no significant difference in the expression of GCLC,
GCLM, GSS, GSR and GSTP1 mRNA between 293/mock
and 293/B5-11 cells (Fig. 5a). GCLC and GCLM are
catalytic and modifier subunits of GCL.
GSH is synthesized from Glu, Cys and Gly [17]. We
therefore measured the cellular amino acid contents in
the ABCB5- and Abcb5-transfected cells. Figure 5b dem-
onstrates the relative amounts of 13 amino acids that
could be quantified by HPLC analysis. The amounts of
these amino acids in 293/mock, 293/B5-11 and 293/
mb5-8 cells are listed in Table 2. Among the GSH com-
ponent amino acids, the cellular content of Glu was up-
regulated in 293/B5-11 and 293/mb5-8 cells (Fig. 5b).
The amount of Gly in 293/B5-11 and 293/mb5-8 cells
was similar to that in 293/mock cells. The amount of
Cys could not be quantified. We also tried to measure
the Cys content using other derivatizing reagents, such
as AQC and 4-fluoro-7-sulfobenzofurazan; however, a
Cys peak was not detected. These results suggest that
the increase in the cellular content of Glu was one of
the reasons for the upregulation of GSH content in the
ABCB5- and Abcb5-transfected cells. In this experiment,
we also observed upregulation of Asp and Ala, and
downregulation of Pro, Phe and Tyr in 293/B5-11 and
293/mb5-8 cells (Fig. 5b). These results also suggest the
possible effect of ABCB5/Abcb5 on the cellular contents
of specific amino acids.
Discussion
Several mRNA isoforms of human ABCB5 have been re-
ported to date [18–21]. Of these, ABCB5β mRNA, which
is highly expressed in human melanoma cells, encodes
an 812-amino acid polypeptide with an N-terminal
hydrophobic region with six predicted transmembrane
segments and a C-terminal nucleotide-binding region
[18, 21–23]. In a previous study, we have identified an-
other mRNA isoform of ABCB5 that shares a strong
homology with ABCB1 and encodes a full-sized ABC
transporter that consists of two homologous halves, each
containing a hydrophobic region with six predicted
transmembrane segments and a nucleotide-binding re-
gion. The full-length human ABCB5-transfected 293/B5-
11 cells showed resistance to doxorubicin, paclitaxel and
docetaxel [9]. Expression of full-length ABCB5 in Sac-
charomyces cerevisiae conferred resistance to rhodamine
123, daunorubicin and FK506 [24]. These results suggest
that the full-length ABCB5 functions as a multidrug ef-
flux pump.
In the present study, we further screened potential
substrates of ABCB5 and found that ABCB5-transfected
cells showed higher resistance to BSO, an inhibitor of
GCL, than the mock-transfected cells (Fig. 1). The de-
gree of BSO resistance of ABCB5 transfectants depended
Fig. 4 Effect of BSO on cellular glutathione content in ABCB5- and Abcb5-transfected cells. Cellular glutathione content was determined using a
glutathione assay kit. Cells were cultured for 2 days in the absence or presence of various concentrations of BSO. a Cellular glutathione content in
293/mock, 293/B5-11 and 293/mb5-8 cells in the absence of BSO. b Cellular glutathione content in 293/mock, 293/B5-11 and 293/mb5-8
cells incubated with various concentrations of BSO for 2 days. Data are presented as relative to the value in the absence of BSO. The data are presented as
mean ± SD of triplicate determinations. Asterisks show p< 0.05 by two-sided t-test
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on the ABCB5 expression level. Murine Abcb5-trans-
fected 293/mb5-8 cells also showed BSO resistance. The
ABCB5- and Abcb5- transfected cells also showed resist-
ance to MSO, another GCL inhibitor that shares strong
structural similarity with BSO. These results indicate the
direct relationship between ABCB5 expression and BSO
resistance. To explore the BSO resistance mechanism of
the ABCB5- and Abcb5-transfected cells, we first exam-
ined the possibility that ABCB5/Abcb5 decreases the
intracellular accumulation of BSO in the transfectants.
However, the BSO uptake levels in 293/B5-11 and 293/
mb5-8 cells were similar to those in 293/mock cells
(Fig. 2). BSO is a small hydrophilic compound with a
molecular mass of 222. We have reported that 293/B5-
11 cells showed resistance to docetaxel, doxorubicin,
daunorubicin, vincristine, etoposide and actinomycin D
[9]. All of these are ABCB1 substrates, which are amphi-
philic molecules with a molecular mass of 500–1000.
Therefore the result that ABCB5/Abcb5 did not affect
the cellular accumulation of BSO may not be controver-
sial to previous findings.
BSO and MSO bind and inhibit GCL. They cause de-
pletion of cellular glutathione, which is the primary
mechanism of their cytotoxic effect [25, 26]. We showed
that the cellular GSH content in the ABCB5- and
Abcb5-transfected cells was significantly higher than that
in the mock-transfected cells (Fig. 3). A transport assay
revealed that the upregulation of cellular glutathione
was not caused by the ABCB5-mediated transport of
GSH. We next examined whether the BSO resistance of
293/B5-11 and 293/mb5-8 cells is attributed to the effect
of BSO on the depletion of cellular glutathione. As
shown in Fig. 4b, the suppressive effect of BSO on the
cellular glutathione content was weaker in the ABCB5-
and Abcb5-transfected cells than in the mock-
transfected cells, despite the cells having the same level
of intracellular BSO. These results suggest that ABCB5/
Abcb5 alters cellular glutathione synthesis or metabol-
ism, and thereby reduces the effect of BSO. ABCC1 is
known to export glutathione conjugates such as leuko-
triene C4, and co-export anticancer agents such as doxo-
rubicin with GSH [27, 28]. BSO reduces transport of
doxorubicin in ABCC1-overexpressing cells by downreg-
ulating the cellular GSH level [28]. The cellular GSH
content in ABCC1-transfected cells was lower than that
in control cells [29]. We found that ABCC1-transfected
KB/MRP1 cells showed hypersensitivity to BSO com-
pared with the parental KB-3-1 cells (data not shown).
These results also suggest that the cellular GSH content
correlates with BSO sensitivity. However, ABCB5- and
Abcb5-transfected cells are completely different from
ABCC1-transfected cells in regard to the effect of BSO.
Fig. 5 Glutathione metabolism of ABCB5- and Abcb5-transfected cells. a mRNA expression of genes encoding enzymes involved in glutathione
metabolism. PCR cycles were as follows: GCLC, 29, 32 and 35; GCLM, 27, 30 and 33; GSS, 29, 32 and 35; GSR, 27, 30 and 33; GSTP1, 27, 30 and 33;
GAPDH, 20, 22 and 24. b Cellular amino acid contents in 293/B5-11 and 293/mb5-8 cells. The methanol extracts of cells were derivatized using 4-
fluoro-7-nitro-2,1,3-benzoxadiazole and subjected to HPLC. Data represent the percentage relative to 293/mock cells for each amino acid. The data
are presented as mean ± SD of triplicate determinations
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In addition, GSH is a transport substrate of ABCC1, but
not of ABCB5/Abcb5.
Glutathione is synthesized from Glu, Cys and Gly by
two enzymes, GCL and GSS [17]. GCL is composed of
the catalytic subunit, GCLC, and the modifier subunit,
GCLM [30]. Co-transfection of GCLC and GCLM
cDNAs into COS cells resulted in high cellular GSH
levels [31]. However, our cDNA microarray and RT-PCR
analyses showed no differences between 293/mock and
293/B5-11 cells in the mRNA expression of genes en-
coding glutathione-metabolizing enzymes including
GCLC and GCLM (Fig. 5a). Among the transporters,
only the expression of ABCB5 was different, but again
there were no other differences between 293/mock and
293/B5-11 cells (data not shown). Glutathione synthesis
is regulated by the availability of its substrates [17].
Therefore, we measured the content of cellular amino
acids in the ABCB5- and Abcb5-transfected cells using
HPLC, and found that the Glu content was upregulated
in these transfectants (Fig. 5b). This may be one of the
reasons for the upregulation of the GSH content in the
ABCB5- and Abcb5-transfected cells. We also observed
upregulation of Asp and Ala, and downregulation of
Pro, Phe and Tyr in 293/B5-11 and 293/mb5-8 cells
(Fig. 5b). These results suggest the possible effect of
ABCB5/Abcb5 on the cellular contents of specific amino
acids.
Currently, there is accumulating evidence that stem
cells or tumor-initiating cells express various trans-
porters. ABCG2 is expressed in hematopoietic stem cells
and is a determinant of the side-population phenotype.
[7]. ABCG2 exports various toxic substances and
xenobiotics out of cells, and therefore protects stem cells
from such toxic effects. The CD44 variant isoform
expressed in cancer stem cells interacts with xCT, a sub-
unit of cystine/glutamate antiporter, promotes glutathi-
one synthesis and increases the cellular GSH level [32].
GSH plays a major role in cellular defenses against react-
ive oxygen species, and therefore the expression of the
CD44 variant isoform protects the cells from oxidative
stress [32–34]. ABCB5 is expressed in limbal stem cells
and is required for corneal development and repair [11].
ABCB5 has also been reported to be expressed in human
melanoma tumor-initiating cells [10]. ABCB5-positive
melanoma cells inoculated into immunodeficient mice
showed greater tumorigenic capacity than the ABCB5-
negative melanoma cells [10]. These results suggest that
ABCB5 protects stem cells and tumor-initiating cells
from the toxic effect of various poisons. The identifica-
tion and analysis of cancer stem cell markers are of great
interest in current cancer cell biology and are likely to
contribute to the development of new strategies for can-
cer treatment.
Conclusions
Human ABCB5- and murine Abcb5-transfected cells
showed resistance to BSO, an inhibitor of glutathione
synthesis. BSO was not a transport substrate of ABCB5.
The cellular glutathione content in the ABCB5/Abcb5-
transfected cells was significantly higher than that in the
mock-transfected cells, because the ABCB5/Abcb5-trans-
fected cells were more resistant to the glutathione-
depleting effect of BSO than the mock-transfected cells.
The current results suggest that ABCB5/Abcb5 upregu-
lates cellular glutathione levels, and thereby protects
cells from various poisons.
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Table 2 Cellular amino acids’ content in 293/mock, 293/B5-11
and 293/mb5-8 cells
Amino acid 293/mock 293/B5-11 293/mb5-8
Asp 1.9 ± 0.45 (100) 2.4 ± 0.42 (130) 2.6 ± 0.40 (130)
Glu 8.3 ± 1.5 (100) 12 ± 1.3 (140) 14 ± 1.2 (170)
Gly 4.3 ± 0.28 (100) 4.9 ± 0.82 (110) 3.8 ± 0.24 (87)
Gln 54 ± 7.5 (100) 55 ± 7.5 (100) 42 ± 4.2 (77)
Thr 5.6 ± 0.86 (100) 5.7 ± 0.75 (100) 4.9 ± 0.59 (88)
Ala 0.91 ± 0.12 (100) 1.0 ± 0.19 (110) 1.4 ± 0.15 (150)
Pro 1.9 ± 0.35 (100) 1.4 ± 0.25 (72) 1.4 ± 0.20 (76)
Val 1.6 ± 0.071 (100) 1.5 ± 0.025 (94) 1.5 ± 0.075 (92)
Ile 1.6 ± 0.087 (100) 1.4 ± 0.13 (86) 1.3 ± 0.18 (83)
Leu 1.6 ± 0.23 (100) 1.3 ± 0.14 (81) 1.2 ± 0.18 (78)
Phe 1.1 ± 0.087 (100) 0.80 ± 0.058 (75) 0.78 ± 0.060 (73)
Lys 0.27 ± 0.019 (100) 0.33 ± 0.031 (120) 0.30 ± 0.063 (110)
Tyr 1.0 ± 0.19 (100) 0.57 ± 0.085 (55) 0.60 ± 0.079 (57)
The methanol extracts of the cells were derivatized using 4-fluoro-7-nitro-2,1,3-
benzoxadiazole and subjected to HPLC analysis. Each value represents the amino
acid’s content (nmol/106 cells). Numbers in parentheses are the percentage relative
to 293/mock cells. The data are presented as mean± SD of triplicate determinations
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